Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
复制标题
DOI：
10.1111/jcpt.12397
复制
发表时间：
2016-06-01
影响因子：
2
通讯作者：
Aguirre, C.
中科院分区：
文献类型：
--
作者：
Garcia, M.;Aranburu, M. A.;Aguirre, C.
已知和客观：大疱性类天疱疮已报告与格列汀类药物有关。我们描述了一种情况下，回顾文献和分析大疱性类天疱疮记录在欧洲药物警戒数据库，EudraVigilance.Case摘要：一个74岁的女子，治疗与vildagelatin/二甲双胍12个月，开发大疱性类天疱疮，皮肤活检证实。症状在停用维达鲁肽/二甲双胍后7个月内消退。新内容和结论：EudraVigilance中的检索显示，除阿格列汀外，大疱性类天疱疮和格列汀类药物均为阴性。这些发现扩展了将格列汀与这种潜在的严重疾病联系起来的证据。
What is known and objective: Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance.Case summary: A 74-year-old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal.What is new and conclusion: A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.